MONTHLY DOSE

MARCH 2019

MONTHLY DOSE

APRIL 2020

Biocon's insulin manufacturing facility in Malaysia gets EIR with VAI

classification from USFDA

Cipla announces successful completion of Phase-3 clinical study for generic

version of GSK’s Advair Diskus

Aurobindo Pharma calls off USD1bn deal with Sandoz after failing to get FTC

nod

Lupin’s Aurangabad facility gets an EIR form USFDA

Lupin launches Mycophenolic Acid DR Tablets USP

Granules Vizag facility gets EU GMP approval

Lupin’s Nagpur facility receives EIR from USFDA

USFDA requested all manufacturers of SMS Pharmaceuticals to withdraw

Ranitidine products from the US market

DRL’s API manufacturing plant 5 at Miryalaguda, Telangana received an EIR

from the USFDA

Hydroxychloroquine production scaled up for Zydus Cadila

Dr. Reddy announces the launch of an authorized generic version of NitroDur

(nitroglycerin) Transdermal Infusion System in the US market

Dr. Reddy announces the launch of Amphetamine sulfate tablets in the US

market

Biocon and Mylan Launch Fulphila, Biosimilar Pegfilgrastim, in Australia

Lupin’s Mandideep Unit II facility receives an EIR from USFDA

Biocon Biologics receives EIR from USFDA for 2 facilities

Shilpa Medicare receives EIR from USFDA for Raichur API Unit

Wockhardt receives QIDP status for antibiotic WCK 6777 from USFDA

Aurobindo’s formulation facility Unit IV classified as VAI by USFDA

Shilpa Medicare launches an anticancer drug DASASHIL

Natco Pharma gets EIR for Kothur formulation facility

Gufic Lifesciences gets ANVISA, Brazil approval for its Injectable plant

Lincoln Pharma received approval to manufacture Hydroxychloroquine and

Hydroxychloroquine Sulphate Tablets

DRL announces the launch of Fenofibrate Tablets USP, in the US market

Natco's Vizag formulation facility receives final approval for its sANDA

product from the USFDA

Biocon and Mylan launch Fulphila biosimilar Pegfilgrastim in Canada

Strides develops and commences export of Favipiravir Antiviral Tablets

Hester Biosciences collaborates with IIT Guwahati for Covid-19 vaccine

Fire mishap at Suven Lifesciences unit in Hyderabad Glenmark received approval from DCGI to conduct clinical trials in India on

Favipiravir Antiviral tablets for Covid-19 patients

Lupin’s Pithampur Unit-1 facility received an EIR from USFDA

Morepen Laboratories gets ISO-13485 certification for its medical devices

manufacturing facility at Baddi

IPCA seeks clarification from USFDA on Hydroxychloroquine risk

Govt frees exports of all APIs, formulations except paracetamol

AIIMS issues guidelines on reuse of PPE, citing depletion of stocks

ICMR releases plasma trials protocol, seeks registrations

Pharmacists to ration drugs to avoid shortage

WHO prematurely publishes remdesivir results

Novartis announces plan to initiate clinical trial of canakinumab for patients with

Covid-19 pneumonia

Industry

Company

Global

News for the Month

Source: Media Reports and Company Press Releases

Company API Strengths Indications Brand (Company) Mkt Size

Cadila Lamotrigine ER

Tablets

25/50/100/200/

250/300mg

Indicated for the treatment of certain

types of seizures

Lamictal XR

(GlaxoSmithKline)

-

Cadila Perphenazine Tablets 2/4/8/16mg Indicated for the treatment of schizophrenia and for the control of

severe nausea and vomiting in

adults

Trilafon (Apicore) -

Cipla Albuterol Sulfate

Inhalation Aerosol

90mcg (base)/

actuation

Used for treatment of acute episodes of bronchospasm or prevention of

asthmatic symptoms

Proventil HFA Inhalation Aerosol (Merck Sharp &

Dohme Corps)

USD153mn

Granules Butalbital, Acetaminophen and

Caffeine Capsules

50/300/40mg Used for the relief of the symptom complex of tension (or muscle

contraction) headache

Butalbital, Acetaminophen and

Caffeine Capsules

(Nexgen Pharma, Inc.)

USD42mn

Cadila Imatinib Mesylate

Tablets

100/400mg Used to treat certain types of leukemia (blood cancer), bone

marrow disorders, skin cancer and

tumors of the stomach and digestive

system

Gleevec (Novartis

Pharmaceuticals)

USD868mn

(July 2018)

Cadila Baclofen Tablets 5mg Used to treat muscle spasms caused by certain conditions such as

multiple sclerosis, spinal cord

injury/disease

Ozobax (Metacel

Pharmaceuticals')

-

Cadila Erlotinib Tablets 25/100/150mg Used to treat non-small cell lung cancer or pancreatic cancer that has

spread to other parts of the body

(metastatic)

Tarceva Tablets

(Genentech Inc.)

USD212mn (Annual sales

March 2019)

Aurobindo Fluoxetine Tablets 10/20mg Indicated for the acute and

maintenance treatment of major

depressive disorder in adult patients

and in pediatric patients aged 8 to

18 years

Prozac (Eli Lilly) USD42mn

JB Chemicals Carbamazepine ER

Tablets

100/200/400mg Indicated for treatment of Epilepsy

and Trigeminal Neuralgia

Tegretol XR Tablet (Novartis Pharmaceuticals

Corp.)

USD128mn

Granules Vigabatrin for Oral

Solution

500mg Indicated as adjunctive therapy Sabril (Lundbeck

Pharmaceuticals)

USD225mn

Final ANDA Approvals:

Source: Media Reports and Company Press Releases

Company API Strengths Indications Brand (Company) Mkt Size

Cadila Empagliflozin

Tablets

10/25mg Used together with diet and exercise to improve blood sugar

control in adults with Type 2

diabetes mellitus

Jardiance

(Boehringer Ingelheim)

USD3.4bn

(Sept 2019)

Cadila Macitentan

Tablets

10mg Indicated for the treatment of

pulmonary arterial hypertension

Opsumit Tablets (Actelion) -

Alembic Alcaftadine Ophthalmic

Solution

0.25% Indicated for the prevention of itching associated with allergic

conjunctivitis

Lastacaft Ophthalmic

Solution (Allergan Inc.)

USD7mn

Glenmark Dapagliflozin and Saxagliptin

Tablets

10/5mg Used to improve blood sugar control in adults with type 2

diabetes mellitus

Qtern (AstraZeneca AB) USD10.4mn

Lupin Arformoterol Tartrate

Inhalation

Solution

15mcg (base)/2mL

Unit dose vials

Indicated for long term maintenance treatment of bronchoconstriction in

patients with chronic obstructive

pulmonary disease

Brovana (Sunovion

Pharmaceuticals Inc.)

USD489mn

Tentative ANDA Approvals:

Source: Media Reports and Company Press Releases

Company API Strengths Indications Brand (Company) Mkt Size

Strides Flucytosine Capsules 250/500mg Indicated only in the treatment of serious infections caused by

susceptible strains of Candida and/

or Cryptococcus

Ancobon Capsules

(Bausch Health US, LLC.)

USD45mn

Granules Trospium Chloride

ER Capsules

60mg Muscarinic Antagonist indicated for

the treatment of overactive bladder

Sanctura XR Capsules

(Allergan, Inc)

USD25mn

Caplin Point Ropivacaine Hydrochloride

Injection

0.2 % in 40mg/20mL

(2mg/mL), 0.5 %

in 100mg/20mL (5mg/mL), 0.5 %

in 150mg/30mL

(5mg/mL) and 1 % in

200mg/20mL

(10mg/mL)

Single-dose vial

A long acting local anesthetic drug used for surgery or acute pain

management

NAROPIN Injection (Fresenius Kabi USA

LLC.)

USD34mn

Final ANDA Approvals:

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance

Companies

Price

Change

1 M 6 M 12 M

Aarti Drugs Ltd 715 41.4% 32.7% 14.7%

Abbott India Ltd 17668 14.3% 48.4% 137.6%

Ajanta Pharma Ltd 1486 8.7% 45.0% 50.1%

Alembic Ltd 50 41.0% 0.00% 20.0%

Alembic Pharmaceuticals Ltd 746 39.8% 36.5% 34.1%

Alkem Laboratories Ltd 2608 12.0% 32.0% 51.7%

Apollo Hospitals Enterprise Ltd 1394 22.5% -4.6% 14.7%

AstraZeneca Pharma India 3032 26.8% 11.9% 28.4%

Aurobindo Pharma Ltd 626 51.5% 35.2% -23.5%

Biocon Ltd 354 30.8% 42.5% -40.3%

Bliss GVS Pharma Ltd 98 -2.5% -27.3% -41.8%

Cadila Healthcare Ltd 324 21.3% 29.6% -0.3%

Caplin Point Laboratories Ltd 351 24.3% -11.2% -3.5%

Cipla Ltd 590 39.4% 27.0% 4.5%

Divi's Laboratories Ltd 2333 17.4% 34.3% 33.8%

Dr. Reddy's Laboratories Ltd 3937 26.3% 42.6% 34.2%

Dr. Lal PathLabs Ltd 1587 13.2% 0.3% 52.7%

Eris Lifesciences Ltd 501 36.1% 13.1% -20.5%

FDC Ltd 245 24.9% 35.5% 42.2%

Fortis Healthcare Ltd 127 0.9% -8.6% -8.0%

GSK Pharmaceuticals Ltd 1445 16.0% -10.0% 12.7%

Glenmark Pharmaceuticals Ltd 337 63.6% 8.9% -47.1%

Granules India Ltd 163 13.2% 25.7% 45.1%

Gufic Biosciences Ltd 66 40.8% -6.9% -16.4%

HealthCare Global Enterprises Ltd 71 -5.9% -39.3% -65.6%

Hester Biosciences Ltd 1337 44.5% -19.6% -6.8%

Hikal Ltd 112 60.4% -5.7% -36.6%

Indoco Remedies Ltd 232 10.7% 45.2% 15.6%

Indraprastha Medical Corp. Ltd 39 15.9% 2.6% 2.7%

IOL Chemicals and Pharma Ltd 289 64.2% 56.4% 61.3%

IPCA Laboratories Ltd 1619 16.6% 65.9% 69.8%

J.B. Chemicals & Pharma Ltd 557 9.6% 68.2% 62.0%

Jubilant Life Sciences Ltd 400 60.9% -24.4% -39.3%

Kopran Ltd 28 10.1% 1.8% -26.9%

BSE Health Care Index Price Performance

Companies

Price

Change

1 M 6 M 12 M

Laurus Labs Ltd 512 58.8% 40.7% 34.1%

Lincoln Pharmaceuticals Ltd 156 16.6% -3.1% -13.8%

Lupin Ltd 835 41.6% 14.4% -4.1%

Mangalam Drugs and Organics Ltd 72 138.2% 121.1% 38.1%

Marksans Pharma Ltd 20 43.7% 36.5% -15.3%

Medicamen Biotech Ltd 261 44.4% -23.4% -49.2%

Merck Ltd 4322 18.6% -9.2% 16.3%

Morepen Laboratories Ltd 18 92.0% 11.7% 10.0%

Narayana Hrudayalaya Ltd 279 12.9% 1.9% 38.2%

Natco Pharma Ltd 611 20.7% 2.9% 12.3%

Nectar Lifesciences Ltd 14 43.6% 9.1% -13.1%

Neuland Laboratories Ltd 452 59.5% -8.9% -35.8%

Novartis India Ltd 626 24.6% -9.7% -9.5%

Opto Circuits India Ltd 4 126.0% -8.8% -48.8%

Panacea Biotec Ltd 172 57.5% 23.4% -10.6%

Pfizer Ltd (India) 4905 21.9% 25.8% 56.8%

Piramal Enterprises Ltd 989 5.3% -41.7% -58.0%

Poly Medicure Ltd 228 -3.3% 11.1% 16.8%

RPG Life Sciences Ltd 246 44.1% 15.7% 4.4%

Sanofi India Ltd 7776 24.6% 17.4% 38.0%

Shalby Ltd 70 51.6% -32.5% -46.6%

Shilpa Medicare Ltd 363 48.3% 32.7% -7.1%

SMS Pharmaceuticals Ltd 43 62.9% 5.5% -28.3%

Strides Shasun Ltd 444 37.5% 13.7% -7.6%

SPARC Ltd 132 36.4% -6.9% -21.9%

Sun Pharmaceutical Industries Ltd 465 32.0% 8.1% 1.7%

Suven Life Sciences Ltd 46 114.7% -83.9% -82.6%

Syngene International Ltd 321 33.1% -2.8% -47.3%

Thyrocare Technologies Ltd 509 2.7% -7.5% 3.8%

Torrent Pharmaceuticals Ltd 2345 18.9% 32.8% 30.8%

Unichem Laboratories Ltd 148 -2.3% -22.1% -22.7%

Vimta Labs Ltd 80 35.3% -32.1% -57.4%

Vivimed Labs Ltd 12 71.2% -15.4% -47.1%

Wockhardt Ltd 256 48.2% -7.0% -38.0%

Source: BSE website; All prices are as on 30th April 2020

Source: BSE website; All prices are as on 30th April 2020

NIFTY PHARMA COMPANIES

Company

Price

(Rs)

Mcap

(Rsmn)

Change

1 M 6 M 12 M

Aurobindo Pharma Ltd. 626 366768 51.54% 35.2% -23.5%

Biocon Ltd. 354 424740 30.8% 42.5% -40.3%

Cadila Healthcare Ltd. 324 331641 21.3% 29.6% -0.3%

Cipla Ltd. 590 474920 39.4% 27.0% 4.5%

Divi's Laboratories Ltd. 2333 619298 17.4% 34.3% 33.8%

Dr. Reddy's Laboratories Ltd. 3937 560623 26.3% 42.6% 34.2%

Glenmark Pharmaceuticals Ltd. 337 95147 63.6% 8.9% -47.1%

Lupin Ltd. 835 378222 41.6% 14.44% -4.1%

Piramal Enterprises Ltd. 989 196932 5.3% -41.7% -58.0%

Sun Pharmaceutical Industries Ltd. 465 1115331 32.0% 8.1% 1.7%

Source: NSE website, Company Research; All prices are as on 30th April 2020

Nifty Pharma Index Vs. Nifty Index

Source: NSE website

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products. PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time. PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-: · PSBPL or its associates financial interest in the subject company: NO · Research Analyst (s) or his/her relative's financial interest in the subject company: NO · PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company. · PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO · Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO · PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months. · The research Analyst has served as officer, director or employee of the subject company: NO PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Terms & Conditions: This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Compliance Officer: Mr. Shyam Agrawal, Email Id: compliance@progressiveshares.com, Contact No.:022-40777500.

Registered Office Address: Progressive Share Brokers Pvt. Ltd, 122-124, Laxmi Plaza, Laxmi Indl Estate, New Link Rd, Andheri West, Mumbai-400053; www.progressiveshares.com Contact No.:022-40777500.